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The rapid expansion of the available genomic data continues to greatly impact biomedical science and medicine.
Fulfilling the clinical potential of genetic discoveries requires the development of therapeutics that can specifically
modulate the expression of disease-relevant genes. RNA-based drugs, including short interfering RNAs and antisense
oligonucleotides, are particularly promising examples of this newer class of biologics. For over two decades, researchers
have been trying to overcome major challenges for utilizing such RNAs in a therapeutic context, including intracellular
delivery, stability, and immune response activation. This research is finally beginning to bear fruit as the first RNA drugs
gain FDA approval and more advance to the final phases of clinical trials. Furthermore, the recent advent of CRISPR,
an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro,
have triggered a major expansion of the RNA-therapeutics field. In this review, we discuss the challenges for clinical
translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an
overview of the applications of RNA-based drugs for modulation of gene/protein expression and genome editing that
are currently being investigated both in the laboratory as well as in the clinic.
Keywords: Antisense oligonucleotide, Clinical trial, CRISPR, Gene editing, Gene therapy, Messenger RNA delivery, mRNA
vaccine, RNA nanoparticle, Short interfering RNA deliveryBackground
Fourteen years after the completion of the human gen-
ome project, our understanding of human genomics
continues to develop at an unprecedented rate. Thanks
to advances in next-generation sequencing technology,
scientists have been able to identify the genetic roots of
many common diseases [1]. Diseases such as cancer [2],
Parkinson’s [3], rheumatoid arthritis [4], and Alzheimer’s
[5] have all had many of their genetic components re-
vealed, bringing us closer than ever to ‘personalized
medicine’ [6]. Thus far, this knowledge has been well
adapted for diagnostic use—but has not yet been fully
translated to pharmaceutical interventions addressing
the genetic defects underlying diseases. Currently, the
two major structural classes of FDA-approved drugs are
small molecules and proteins [7]. Small-molecule drugs,* Correspondence: dgander@mit.edu
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(http://creativecommons.org/publicdomain/zewhich consist predominantly of hydrophobic organic
compounds, typically act by deactivating or inhibiting
target proteins through competitive binding. However,
the proteins that might possess such binding pockets
have been estimated to account for only 2–5% of the
protein-coding human genome [8]. Protein-based drugs
(e.g., antibodies), by contrast, can bind with high specifi-
city to a variety of targets or be used to replace mutated
or missing proteins (e.g., delivering insulin for diabetes).
However, the size and stability of proteins limit their
utility towards many potential disease targets [7]. Thus,
true realization of the therapeutic potential of personal-
ized genomics requires treatments beyond those offered
by current small-molecule and protein therapies.
In summary, both protein and small-molecule drugs
are limited in that they cannot target every disease-
relevant protein or gene. The mRNA and DNA precur-
sors of proteins, however, are promising therapeutically
in that they can be specifically targeted via Watson–
Crick base pairing and, in the case of gene editing,
which aims to permanently change the host’s DNA, rep-
resent an avenue to cure a genetic defect as opposed tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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have emerged as candidates to address diseases at the
gene and RNA levels. Although it has been known since
1990 that nucleic acids can be used to modulate protein
production in vivo [9], therapeutic RNA delivery has
been limited by a number of factors. Naked, single-
stranded RNA is prone to nuclease degradation, can
activate the immune system, and is too large and nega-
tively charged to passively cross the cell membrane—and
must, therefore, be provided with additional means of
cellular entry and escape from endosomes, which trans-
port extracellular nanoparticles into the cytoplasm [10].
As such, the nucleic acid delivery field has centered on
the design of delivery methods and materials that will
transport RNA drugs to the site of interest. In this
review, we provide an overview of the current status of
advances in RNA and RNA–protein therapy, with an
emphasis on materials that have been developed for
RNA delivery and applications of RNA-based drugs for
the modulation of gene/protein expression and gene
editing.
Delivery materials and chemical modifications for
RNA
Delivery materials
Broadly speaking, RNA delivery can be mediated by viral
and non-viral vectors. For viral RNA delivery, there has
been a great deal of interest in engineering adeno-
associated viruses to carry nucleic acid cargo [11]—how-
ever, this section will focus mainly on the development
of non-viral materials (Table 1). Of the non-viral RNA
delivery vehicles, nanoparticles are perhaps the most
studied. Nanoparticle encapsulation of RNA physically
protects nucleic acids from degradation and, depending
on the specific chemistry, can aid in cellular uptake and
endosomal escape. Given their high degree of chemical
flexibility, polymers are commonly used materials for
nanoparticle-based delivery [12]. Typically, cationic poly-
mers are used to electrostatically condense the nega-
tively charged RNA into nanoparticles (Fig. 1a) [13].Table 1 Comparison of clinically relevant RNA delivery platforms
Delivery vehicle Type of RNA in clinical trials Advantages
Naked RNA siRNA, ASO, mRNA No additional materials or
synthesis required
Nanoparticle siRNA, ASO, mRNA Increased half life
Protection from nucleases
Aids in endocytosis and
endosomal escape
Conjugate siRNA, ASO Defined chemical structure
Ability to target specific recep
Limited toxicity due to lack o
excipient materials
ASO antisense oligonucleotide, siRNA short interfering RNAThese positively charged groups often consist of amines
that become protonated at physiological pH (pKa ~7.4),
thought to lead to an ion imbalance that results in endo-
somal rupture [14, 15], although this so-called ‘proton
sponge’ hypothesis has yet to be rigorously demon-
strated for various materials [16]. Regardless of the exact
mechanism by which polymers aid in RNA delivery,
commercially available amine-containing polymers were
some of the earliest non-viral materials adopted for
nucleic acid delivery. Synthetic polymers such as poly-L-
lysine [17], polyamidoamine [18], and polyethyleneimine
[19], as well as naturally occurring polymers such as
chitosan [20], have all been applied to RNA delivery,
with varying levels of success. In addition, some investi-
gators have synthesized polymers specifically for nucleic
acid delivery. Poly(β-amino esters), in particular, have
gained widespread use in DNA delivery owing to their
ease of synthesis and biodegradability [21], but have also
proved to be capable of effecting delivery of short inter-
fering RNA (siRNA) [22–24] and mRNA [25].
Lipids and lipid-like materials represent the second
major class of nanoparticle-based delivery vehicles for
RNA. As with polymers, cationic lipids are often used to
electrostatically bind the nucleic acid. Many laboratories,
however, have started utilizing ionizable lipids, which are
lipids that are positively charged only at acidic pH. This
ionizable behavior is thought to enhance efficacy
through helping with endosomal escape [26] and redu-
cing toxicity [27] as compared with particles that remain
cationic at physiological pH. Lipids are also capable of
self-assembly into well-ordered nanoparticle structures,
known as lipoplexes (Fig. 1b), driven by a combination
of electrostatic interactions with RNA and hydrophobic
interactions [28, 29]. Optimizing the formulation of lipid
nanoparticles (LNPs) by addition of other hydrophobic
moieties, such as cholesterol and PEG-lipid, in addition
to an ionizable/cationic lipid, enhances nanoparticle
stability and can significantly enhance efficacy of RNA
delivery [30]. However, similarly to polymers, it was
found that ionizable lipid structure is the main factorDisadvantages References
Prone to degradation
Immunogenic
Difficulty entering cell
Poor circulation half-life
[63–65, 73–78, 101, 103, 114, 115]
Elevated risk of toxicity with
introducing excipient materials
[12–37, 58–60, 82–85, 106–108,
110–113, 131, 145, 156–159]
tors
f
High doses required
Dependent on chemical
modifications for RNA stability
[38–43, 62]
a b
5-Bromo-uridine 5-methylcytidine 2’-Deoxy 2’-OMe Amide-3 linkage Thioate linkagePseudouridine
RNA cargo
Cationic polymer RNA cargo
Cationic/ionizable lipid
Phospholipid
Cholesterol
PEG
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Fig. 1 Common delivery modalities for RNA. a Schematic depicting polymeric nanoparticles comprising RNA and cationic polymer. b Schematic
depicting lipid nanoparticles containing RNA, a cationic/ionizable lipid, and other hydrophobic moieties (such as cholesterol) commonly used
in nanoparticle formulation. c Chemical structure of a tertiary conjugate between N-acetylgalactosamine (GalNAc) and RNA that is currently
in clinical trials [38]. d Examples of base, sugar, and linker modifications that have been utilized to deliver nucleic acids (modified chemistry
highlighted in blue)
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laboratory has pioneered the use of semi-automated
high-throughput synthesis methods to create libraries of
chemically diverse lipids and lipid-like materials for
RNA delivery [31–35], resulting in highly potent nano-
particles capable of delivering a variety of RNA types to
both the liver [32, 36, 37] and the lung [33] following
systemic delivery in vivo.
As an alternative to nanoparticles, a more conceptually
straightforward and chemically well-defined means of
delivery is to directly conjugate a bioactive ligand to the
RNA that will allow it to enter the cell of interest.
Perhaps the most clinically advanced example of thistechnique is the conjugation of N-acetylgalactosamine
(GalNAc; Fig. 1c), which targets the asialoglycoprotein
receptor on hepatocytes, to siRNA [38]. Unlike many
nanoparticles, which are given intravenously, GalNAc
conjugates are typically dosed subcutaneously and have
shown an ability to rapidly enter systemic circulation and
target the liver [39]. Other conjugates, such as cholesterol
[40], vitamin E [41], antibodies [42], and cell-penetrating
peptides [43], have been explored in the past, although
none but the specialized triantennary GalNAc–siRNA
conjugate has gained any clinical traction (Table 2), sug-
gesting the need for additional work on the design of con-
jugates for efficient delivery of nucleic acids.
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Equally important for effective nucleic acid delivery are
chemical modifications made to the RNA itself, which
can impart degradation resistance to the RNA [44] and
render them unrecognizable by the immune system [45].
This is true of both conjugate delivery systems, which
leave the RNA exposed immediately upon injection, as
well as nanoparticulate delivery systems, which must at
some point expose the RNA to intracellular immune re-
ceptors. RNAs can be modified by means of chemical al-
terations to the ribose sugar (of particular importance is
the 2′ position [45, 46]), the phosphate linkage and the
individual bases (Fig. 1d) [47–50]. RNAs delivered
through nanoparticles, discussed later, are also typically
modified in order to avoid recognition by endosomally
expressed pattern recognition receptors [51]. With few
exceptions, modified RNAs are the gold standard in clin-
ical trials (Table 2). The degree to which the RNA can
be modified and still retain its potency depends, to a
large extent, on the nature of the nucleic acid and its
mechanism of action. For instance, short RNAs such as
siRNAs, which rely on the relatively robust RNA-
induced silencing complex (RISC) [52], can typically be
heavily modified. By contrast, large mRNAs, which must
be effectively translated by ribosomes, are more sensitive
to modifications and utilize naturally occurring RNA
modification such as pseudouridine and 5-methylcytidine
substitution [53]. Indeed, recent studies have shown that
base modification of mRNA can actually decrease potency
in certain situations [54], whereas chemical modification in
siRNAs is almost ubiquitously applied for in vivo use [55].
Applications of RNA-based gene/protein
modulation
Protein downregulation—siRNA, ASOs, and microRNA
In simplistic terms, disease-relevant proteins can be al-
tered in one of two ways: upregulated or downregulated.
The use of RNAs to selectively downregulate proteins
experienced a paradigm shift following the discovery of
siRNA by Fire and colleagues [56]. Short interfering
RNAs are typically 21–23 base-pairs in length and can
selectively bind and degrade complementary mRNA
through the RISC (Fig. 2) [57]. After almost two decades
of research, siRNA-based therapies represent one of the
more clinically advanced platforms for RNA drugs.
Alnylam Pharmaceuticals, in particular, has several
siRNA drugs in clinical trials. Their most advanced drug,
also one of the most advanced siRNA therapeutics, pati-
siran, is a LNP containing siRNA against mutant trans-
thyretin for the treatment of transthyretin amyloidosis
[58]. Patisiran is currently in phase III of clinical trials
[59], having shown significant dose-dependent knock-
down, with minimal adverse events, in phase II trials
[60], and other companies have also invested in the useof lipoplex-based siRNA drugs (Table 2). Increasingly,
however, Alnylam and others have reported significant
progress with the GalNAc conjugate technology
(Table 2). Despite Alnylam’s recent decision to discon-
tinue development of revusiran, a GalNAc–siRNA con-
jugate drug that also treats transthyretin amyloidosis
[61], the company has several more GalNAc conjugates
in its pipeline that utilize a newer ‘enhanced stabilization
chemistry’ [62] that could address the issues that led to
the removal of revusiran from clinical trials [61]. Sur-
prisingly, some of the current clinical trials utilize naked,
albeit chemically modified, siRNAs. Almost all of these
naked siRNAs are delivered locally (Table 2), reducing
the risk of RNA degradation and systemic immune acti-
vation compared with that associated with systemic
delivery. An intriguing use of naked siRNA is Silenseed’s
siG12D LODER, which encapsulates siRNA targeted
against the KRAS oncoprotein in an implantable and
degradable polymeric matrix for the treatment of pan-
creatic cancer [63, 64]. However, there is concern that
the positive effects of such treatments might in some
cases be mediated by the induction of non-specific and
immunological mechanisms such as siRNA binding to
toll-like receptors [65].
Despite its significant presence in clinical trials, siRNA
is not the only, or even the first, RNA drug to be investi-
gated for protein knockdown at the clinical stage. The
first RNA drugs widely used in clinical trials were anti-
sense oligonucleotides (ASOs). Like siRNA, ASOs are
designed to block protein translation through Watson–
Crick base-pairing with the target mRNA [66] and can
be modified to improve stability [67]. The ASOs, how-
ever, inhibit protein production through a variety of
mechanisms, such as sterically blocking ribosome at-
tachment or eliciting RNase-H activation [68]. They can
also promote exon skipping (a form of RNA splicing
which leaves out faulty exons), which allows for the dele-
tion of faulty sequences within proteins [69], and, in
some cases, can even lead to protein upregulation, which
could be used therapeutically in diseases where certain
genes are repressed [70]. An additional utility of ASOs is
their ability to enter cells without the use of a transfec-
tion reagent, although this uptake does not always lead
to therapeutic action [71]. Four ASOs have been clinic-
ally approved, all of which are chemically modified and
used without a delivery vehicle, representing the only
RNA drugs for protein modulation to be cleared by the
FDA so far. The most recent, Spinraza (nusinersen), is
injected intrathecally to treat spinal muscular atrophy
[72]. It joined Exondys 51 (eteplirsen), an intravenously
infused ASO for treatment of Duchenne muscular dys-
trophy [73], Vitravene (fomivirsen), an intravitreally
injected ASO indicated for the treatment of ocular cyto-
megalovirus [74], and Kynamro (mipomersen), which is
ASO
siRNA sgRNA
Rnase H
RISC
Ribosome
CRISPR-Cas9
Cleaved
DNA
Protein expression
Cleaved
mRNA
Protein
knockdown
Protein
knockout
I.
II. IV.
mRNA
AAAAA
AAAAA
AAAAA
AAAAA
III.
I
II
III
Cas9 IV
+
Fig. 2 Regulation of gene and protein expression using RNA. Once delivered into the cells, RNA macromolecules can utilize diverse intracellular
mechanisms to control gene and protein expression. (I) Hybridization of antisense oligonucleotides (ASOs) to a target mRNA can result in specific
inhibition of gene expression by induction of RNase H endonuclease activity, which cleaves the mRNA–ASO heteroduplex. (II) Short interfering
RNA (siRNA) is recognized by the RNA-induced silencing complex (RISC), which, guided by an antisense strand of the siRNA, specifically binds and
cleaves target mRNA. (III) In vitro transcribed mRNA utilizes the protein synthesis machinery of host cells to translate the encoded genetic information
into a protein. Ribosome subunits are recruited to mRNA together with a cap and poly(A)-binding proteins, forming a translation initiation complex.
(IV) In the CRISPR–Cas9 system, co-delivery of a single guide RNA (sgRNA) together with the mRNA encoding the Cas9 DNA endonuclease allows
site-specific cleavage of double-stranded DNA, leading to the knockout of a target gene and its product. CRISPR, clustered regularly interspaced short
palindromic repeats
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apolipoprotein B for the treatment of hypercholesterol-
emia [75, 76]. There are still several ASOs in clinical
trials, the majority of which are delivered without a
vehicle (Table 2). Of particular interest are studies by
Ionis Pharmaceuticals utilizing a GalNAc–ASO conju-
gate similar to that developed by Alnylam to deliver
siRNA. Optimism from such approvals and clinical stud-
ies has also led researchers to continue investigation of
ASOs to treat diseases such as amyotrophic lateral scler-
osis (ALS) [77] and spinocerebellar ataxia [78].
An emerging, albeit less clinically advanced, RNA-
based platform for protein knockdown is microRNA
(miRNA). Endogenous microRNAs are non-coding
RNAs that act as key regulators for a variety of cellular
pathways, and are often downregulated in diseases [79].
Thus, exogenous microRNAs, or microRNA mimics,
delivered therapeutically could be used to knockdown
several proteins simultaneously, which is particularly
useful in diseases such as cancer where having a single
disease-relevant target is rare [80]. It is also worth not-
ing that a rare subset of microRNAs is thought to
enhance protein production, and that targeting of gene-suppressing microRNAs using ASOs could also be used
to increase protein production [81]. The majority of
current clinical trials involving microRNA are screens to
investigate microRNA involvement in certain diseases,
although there are several ongoing animal studies utiliz-
ing microRNA delivery. Examples include the use of
LNPs to treat a mouse model of colorectal cancer [82],
and polymeric nanoparticles to deliver microRNA to
the heart to treat fibrosis [83]. The first microRNA
mimic therapy to enter clinical trials was MRX-34—a
liposomal-encapsulated microRNA mimic from Mirna
Therapeutics meant to treat a variety of cancers [84].
However, the company terminated the study earlier in
2017 after reports of several immune-related severe
adverse events [85]. The fact that the adverse events
were immunological in character further highlights
the importance of RNA modification for clinical ap-
plications, as such modifications remain one of the
most important means of evading immune detection
for RNA drugs. Chemical modification of miRNA
mimics in particular, however, might prove challen-
ging owing to the complex nature of miRNA-induced
gene regulation [86].
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Expression of disease-relevant proteins can be achieved
by intracellular delivery of plasmid DNA (pDNA) or
messenger RNA (mRNA). Application of DNA or
mRNA as protein intermediate enables expression of
virtually any desired protein inside the host cells and
tissues. This approach can address formulation and
delivery challenges encountered with protein-based
drugs, especially those aimed at intracellular targets [87].
mRNA-based therapeutics in particular offer several
advantages over pDNA, including rapid and transient
protein production, no risk of insertional mutagenesis,
and greater efficacy of non-viral delivery by virtue of
mRNA cytoplasmic activity (Fig. 2) [88]. Since the first
pre-clinical studies in the 1990s, mRNA technology has
greatly developed and now holds the potential to
revolutionize vaccination, protein-replacement therapies,
and treatment of genetic diseases, consequently gaining
a considerable level of interest among the scientific com-
munity and biotech industry [53].
The delivery of mRNA therapeutics has been facilitated
by significant progress in maximizing the translation and
stability of mRNA, preventing its immune-stimulatory
activity and the development of in vivo delivery technolo-
gies, some of which are discussed below. The 5′ cap and
3′ poly(A) tail are the main contributors to efficient trans-
lation and prolonged half-life of mature eukaryotic
mRNAs. Incorporation of cap analogs such as ARCA
(anti-reverse cap analogs) and poly(A) tail of 120–150 bp
into in vitro transcribed (IVT) mRNAs has markedly
improved expression of the encoded proteins and
mRNA stability [89, 90]. New types of cap analogs,
such as 1,2-dithiodiphosphate-modified caps, with re-
sistance against RNA decapping complex, can further
improve the efficiency of RNA translation [91].
Replacing rare codons within mRNA protein-coding
sequences with synonymous frequently occurring
codons, so-called codon optimization, also facilitates
better efficacy of protein synthesis and limits mRNA
destabilization by rare codons, thus preventing accel-
erated degradation of the transcript [92, 93]. Similarly,
engineering 3′ and 5′ untranslated regions (UTRs),
which contain sequences responsible for recruiting
RNA-binding proteins (RBPs) and miRNAs, can en-
hance the level of protein product [53, 94]. Interest-
ingly, UTRs can be deliberately modified to encode
regulatory elements (e.g., K-turn motifs and miRNA
binding sites), providing a means to control RNA ex-
pression in a cell-specific manner [95]. Some of the
previously discussed RNA base modifications such as
N1-methyl-pseudouridine have not only been instrumen-
tal in masking mRNA immune-stimulatory activity but
have also been shown to increase mRNA translation by
enhancing translation initiation [96, 97]. In addition totheir observed effects on protein translation, base modifi-
cations and codon optimization affect the secondary
structure of mRNA, which in turn influences its transla-
tion [98]. Understanding the importance of, and the ability
to predict, the folding structure of mRNA could aid engin-
eering of mRNA therapeutics—however, the accuracy of
available prediction tools is currently limited. Despite the
plethora of carriers studied for other types of RNA drugs,
mRNA molecules are significantly larger (600–
10,000 kDa) than the previously discussed siRNAs
(~14 kDa) and ASOs (4–10 kDa), which poses an add-
itional challenge for delivery of mRNA therapeutics [99].
Accommodation of large and charged mRNAs into nano-
particles and their effective intracellular release has been
shown to require fine-tuning of existing formulations and
the development of a new-generation of biomaterials with
higher potency [36, 37].
Therapeutic applications of mRNA that are currently
being explored are vaccinations against cancer and infec-
tious disease, protein-replacement therapy, and gene
editing. A comprehensive list of ongoing clinical trials
involving mRNA can be found in Table 2. mRNA
vaccines are in the most-advanced stages of clinical
development, following in the footsteps of competing
DNA and protein-based technologies. Synthetic
mRNA vaccines allow simultaneous delivery of a wide
variety of antigens and are both faster and easier to
manufacture at low cost in comparison with other
systems, enabling a more-rapid response towards emer-
ging pathogens [100]. Additionally, immune responses
generated by naked mRNA can be beneficial for vaccin-
ation purposes [101, 102]. Immunization against infec-
tious diseases using ex vivo mRNA-transfected dendritic
cells (DCs) is now being pursued in clinical trials and has
demonstrated good safety profiles and ability to induce
antigen-specific T-cell responses [103].
Another RNA vaccination approach is the use of self-
amplifying mRNA replicons that have been developed to
extend the duration and magnitude of antigen expres-
sion as well as boost the immune response [104, 105]. In
a recent study, replicon vaccines formulated into nano-
particles comprising repeatedly branched dendrimer
(tree-like) molecules have generated protective immunity
against a broad spectrum of lethal pathogens, including
Zika, Ebola and influenza viruses [106]. Conventional,
modified mRNAs are also being explored for vaccination
[105]. Lipid-nanoparticle-encapsulated mRNAs encoding
pre-membrane and envelope glycoproteins of Zika virus
have recently been reported to elicit potent and durable
neutralizing antibody responses in mice and non-human
primates against the virus after intradermal administra-
tion [107]. Moreover, expression of modified mRNA
encoding broadly neutralizing antibody in the liver, after
systemic administration of mRNA–LNPs, has protected
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mRNA vaccines have experienced accelerated develop-
ment and clinical translation driven by the success of
cancer immunotherapy. The majority of approaches
tested in clinical trials employ adoptive-transfer of DCs
transfected with mRNAs coding for tumor-specific anti-
gens (TSAs) and immunomodulation of T cells with
mRNAs expressing chimeric antigen receptors (CARs)
or TSAs [109]. In addition, direct intradermal and sys-
temic administration of LNP-formulated mRNAs coding
for tumor-specific antigens is currently being investi-
gated in the clinic for induction of T-cell immune
responses [100, 110, 111].
By contrast, most mRNA-based protein replacement
therapies are still in the preclinical stages of develop-
ment and involve supplementation of deficient or
aberrant proteins as well as modulation of cell behavior
by expression of exogenous proteins. The in vivo efficacy
of RNA–protein therapy has been demonstrated for a
number of diseases. The majority of the studies prefer-
entially target the liver owing to the well-established and
efficient methods for RNA delivery into liver tissue.
Therapeutically relevant amounts of human FIX
(hFIX) protein were reached and sustained physio-
logical activity for 4–9 days upon a single intravenous
dose of hFIX mRNA-loaded LNPs in mice with hemophilia
B [112, 113]. Similarly, LNPs formulated with mRNA
encoding erythropoietin (Epo) have been shown to elicit a
systemic physiological response in large animals, including
pigs and nonhuman primates [93]. Therapeutic effects of
mRNA have also been demonstrated in other tissues. Lung
delivery of surfactant protein B (SP-B) mRNA protected
mice from respiratory failure [114], whereas myocardial in-
jection of RNAiMAX-formulated mRNA, encoding human
vascular endothelial growth factor A (VEGF-A), improved
heart regeneration after myocardial infarction in mice
[115]. Based on this notion, Astra Zeneca partnered by
Moderna has launched a phase I clinical trial for local
delivery of VEGF mRNA, starting January 2017 [116].
Pre-clinical studies have demonstrated the transla-
tional potential of mRNA-based protein therapy for
both secreted and intracellular protein targets. How-
ever, treatment of chronic diseases might carry an ele-
vated risk of toxicity, associated with the repeated
mRNA–LNP administrations required to sustain
therapeutic levels of protein. Using mRNA for
delivery of gene editing tools could address this chal-
lenge and is discussed below.
Gene editing
The RNA-based technologies discussed above constitute
a powerful means to transiently repress or overexpress
the expression of genes. By contrast, therapeutic gene
editing entails replacement or alteration of geneexpression by introducing site-specific modifications into
the genome of cells, including correction of deleterious
or introduction of protective mutations [117]. While the
majority of current gene editing efforts are focused on
treatment of monogenic disorders, caused by deleterious
changes in a single gene, the expansion of gene editing
and delivery tools makes the treatment of complex poly-
genic diseases such as cardiovascular diseases [118] and
antiviral therapies [119], as well as editing the epige-
nome, more feasible [120]. The discovery of RNA-
guided DNA endonucleases such as Cas9 associated with
CRISPR (clustered regularly interspaced short palin-
dromic repeats), elements composing the prokaryotic
adaptive immune system [121], equipped scientists with
an easy-to-use and efficient platform to alter genomic
information [122]. So-called CRISPR–Cas systems rely
on Watson–Crick base-pairing between a single guide
RNA (sgRNA) and a corresponding DNA target site
followed by a distinct protospacer-adjacent motif (PAM),
a 3–5-nucleotide DNA sequence required for binding of
Cas9 and cleavage of the target sequence, in order to
introduce a double-stranded break (DSB) into a DNA
molecule [123]. DSBs can be repaired by the cells
using non-homologous end joining (NHEJ) and
homology-directed repair (HDR). NHEJ results in sto-
chastic insertions and deletions (‘indels’) causing per-
manent gene knockout, whereas HDR occurs in the
presence of a DNA template containing homology to
regions flanking the DSB site, leading to incorpor-
ation of desired changes encoded in the repair tem-
plate into the genome [124]. A combination of DSBs
can also be used to edit multiple loci by employing
different sgRNAs [125, 126].
To date, the most widely used and well characterized
gene-editing technology is the CRISPR–Cas9 system
with an effector domain originating from Streptococcus
pyogenes (SpCas9). Direct in vivo delivery of spCas9 to
diseased cells has recently been used to correct muta-
tions in genes in animal models of Duchenne muscular
dystrophy (mdx) [127–129], hereditary tyrosynemia type
I (fah) [130, 131], and lethal metabolic liver disease (oct)
[132] and to reduce blood cholesterol in chimeric mice
with humanized liver by knockout of PCSK9 [133]. Ex
vivo editing with spCas9 has been applied to human
hematopoietic stem cells in order to correct sickle cell
anemia caused by mutation in the gene encoding β-
globin, as well as to deplete T cells of expression of
CCR5 to trigger anti-HIV protection or to deplete PD-1
to boost anti-cancer therapy [134]. Despite positive out-
comes, these studies have revealed limitations of the
CRISPR–Cas9 system relevant for clinical translation, in-
cluding (1) imperfect DNA-targeting specificity leading
to off-target effects [135], (2) low efficiency of genome
editing using HDR [136], and (3) challenging delivery of
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viral methods [137].
The DNA-targeting specificity of CRISPR–Cas9 can be
improved by combining optimized design and synthesis
of guide RNAs. In particular, sgRNAs shorter than 20
nucleotides and containing 5′ mismatches have shown
fewer off-target effects [138, 139], whereas chemically
synthesized sgRNAs bearing base modifications at the 5′
and 3′ ends have demonstrated increased on-target
efficacy [140]. Furthermore, improved types of spCas9, such
as high-fidelity spCas9-HF1 [141] or enhanced-specificity
eSpCas9 [142], have been engineered by introducing
specific mutations into spCas9 based on interactions
between a spCas9–gRNA complex and DNA. New RNA-
guided nucleases, such as Cpf1 from Acidaminococcus sp.
(AsCpf1), with the capability to edit the genome of mam-
malian cells have been discovered recently [143, 144]. Cpf1
nuclease mRNA (~1.3 kb) is significantly smaller than
Cas9, with a different PAM requirement and inherently
higher DNA specificity than spCas9, which makes it attract-
ive for clinical use. Off-target effects can be also limited by
decreasing the cellular presence of spCas9 through condi-
tions favoring transient over long-lasting expression, which
can be accomplished by optimizing the delivery method
[140, 145].
Obtaining a better efficiency of genome editing by
HDR will be necessary to address genetic diseases de-
manding a high level of therapeutic product, espe-
cially when edited cells do not display a positive
change in fitness and outcompete their diseased coun-
terparts over time [117]. The efficiency of correction
by HDR can be significantly improved by designing
an asymmetric single-stranded DNA template that an-
neals to the non-target DNA strand, which is the first
to be released from the Cas9–DNA complex [146]. In
addition, a number of studies have reported better
HDR efficacy by using CRISPR–Cas9 in combination
with small-molecule inhibitors of NHEJ, such as DNA
ligase IV or DNA-dependent protein kinase inhibitors
[147, 148]. Alternatively, HDR can be enhanced by
agonists of proteins crucially involved in homologous
recombination such as Rad51 [149]. Recently, other
methods of gene editing with CRISPR–Cas9, called
homology-independent targeted integration (HITI),
have been developed, which exploit the NHEJ repair
mechanism for gene knock-ins [150]. HITI donor
templates are designed to ensure robust gene integra-
tion only when inserted in the correct direction as
otherwise the target DNA would undergo additional
cleavage by Cas9. This method has demonstrated
higher in vitro efficacy of transgene insertion in com-
parison with HDR-dependent editing, but so far when
conducted in vivo it reached only 3–10% of the
knock-in efficiencies.Intracellular delivery of CRISPR-based agents poses
one of the most significant challenges for therapeutic
genome editing owing to the number of essential com-
ponents. CRISPR–Cas9 components can be delivered as
DNA, RNA, RNA–protein complex (RNP), or a combin-
ation of these macromolecules. These macromolecules
are not able to spontaneously enter the cells, relying on
the use of delivery vehicles such as viral vectors, nano-
particles, or physical and mechanical delivery methods
like nucleofection, cell squeezing, or lipofection that
utilize electric field, mechanical force, or cationic lipids
for temporary disruption of the cell membrane [151].
The latter are primarily suited for therapeutic ex vivo
gene editing, while viral vectors and nanoparticles are
mainly used for in vivo gene therapy [152].
Viral delivery of CRISPR–Cas9 has been explored
using lentivirus, adeno-virus, and adeno-associated virus
(AAV) [137]. AAVs are most widely used for gene ther-
apy clinical trials due to their ability to transduce differ-
ent cell types and tissues and their low risk of genomic
integration and low immunogenicity [153]. However,
AAV-limited packaging capacity (~4.5 kb) makes it im-
possible to accommodate all the components of
CRISPR–spCas9, including sgRNA and a donor DNA
template, into a single AAV. Noteworthy is that a host
immune response to AAV-CRISPR–Cas9 has been ob-
served in mice, elicited by Cas9 immunogenicity and
possibly aggravated by its prolonged expression [154].
Complementary to the viral systems, an abundance of
nanoparticles comprising various bio-compatible mate-
rials are being developed for delivery of CRISPR–Cas9.
As with their use in protein modulation, nanoparticles
for gene editing have demonstrated high loading cap-
acity for nucleic acid cargos, ability to modify payload
bio-distribution and pharmacokinetics through active
targeting and formulation, as well as simplicity of manu-
facturing with a high level of control over their physico-
chemical parameters, such as size/shape and kinetics of
payload release [155]. Nanoparticle-based mRNA deliv-
ery of CRISPR–Cas components is therapeutically
attractive owing to the transient nature of mRNA ex-
pression, no risk of genomic integration and mRNA
cytoplasmic activity, alleviating the need to overcome
the nuclear barrier in comparison with pDNA (Fig. 2).
To date, nanoparticle-mediated delivery of spCas9
mRNA has been used in combination with AAVs encod-
ing a sgRNA and a repair template to induce repair of
the Fah gene in a hereditary tyrosinemia in adult animals
[131]. The efficiency of correction was >6% of hepato-
cytes after a single application, much higher than with a
hydrodynamic injection of pDNA (0.4%) previously
reported for the same disease [130]. Similarly, lung deliv-
ery of mRNA encoding zinc-finger nucleases complexed
into chitosan-coated nanoparticles, used in combination
Kaczmarek et al. Genome Medicine  (2017) 9:60 Page 12 of 16with an AAV6-expressing donor template, resulted in
correction of the gene encoding surfactant protein B in
mice with SP-B deficiency and extended their survival
[156]. Interestingly, the combination of mRNA nanopar-
ticle with the virus was superior to AAV alone, reaching
HDR rates in lung cells of ~9%. Recently, a study de-
scribed the synthesis and development of zwitterionic
amino lipids, composed of a sulfobetaine head group
and a polyamine linker with hydrophobic tails, that were
used to formulate nanoparticles capable of simultaneous
in vivo delivery of Cas9 mRNA and sgLoxP to induce
expression of floxed tdTomato in the liver, kidneys, and
lungs of LSL-TdTomato mice [157]. This study shows
the potential of the nanoparticle–RNA platform to ac-
commodate multiple components of CRISPR–Cas9 into
a single carrier, and could possibly be extended to also
include a donor template. Lipid and polypeptide nano-
particles have also been used to deliver RNA–protein
complex of Cas9 and sgRNAs, which is another promis-
ing strategy to ensure the transient cellular presence of
Cas9, significantly reducing off-target effects [158, 159].
However, the therapeutic potential of in vivo RNP deliv-
ery has yet to be demonstrated.
Conclusions
After over two decades of development, RNA therapeu-
tics has become a clinical reality. The design and chem-
istries used to synthesize siRNAs, ASOs, and mRNAs
have advanced to a point where they enable adequate
stability and immune evasion, while at the same time
allowing the maintenance of efficacy and specificity. The
delivery technologies have also greatly progressed thanks
to the discovery of potent and bio-compatible materials,
aided by high-throughput screening technologies. Des-
pite recent setbacks surrounding withdrawal of Alny-
lams’s siRNA–GalNac conjugate [160] and Curevac’s
first mRNA vaccine [100] from clinical trials, nucleic
acid-based therapeutics continue to progress, as
highlighted by the approval of four ASOs by the FDA
[159] and more RNA candidate drugs with improved
chemical modifications entering advanced stages of
human trials (Table 2). In addition, the enormous excite-
ment surrounding CRISPR–Cas genome editing and its
transformational impact on biomedical sciences has
spurred the development of RNA-based delivery ap-
proaches to facilitate clinical translation of CRISPR–Cas
technology. The first US-based human trial conducted
by the University of Pennsylvania will use CRISPR–Cas9
ex vivo to knock out the genes encoding PD1 and T-cell
receptor alpha/beta in T cells isolated from cancer
patients for cancer therapy [161]. The leading CRISPR
biotech companies such as CRISPR Therapeutics [162],
Editas Medicine [163], and Intellia Therapeutics [164]
have programs in advanced pre-clinical stages ofdevelopment in their portfolios and will likely soon fol-
low the clinical route. These companies mostly focus on
disorders affecting liver, lung, and hematopoiesis, while
developing both ex vivo and in vivo delivery approaches
utilizing AAVs, LNPs, and RNPs [162–164]. This high-
lights that safety and delivery remain the major chal-
lenges for RNA-based drugs, especially for RNA–protein
and CRISPR–Cas therapies, and will be shaping the
scope of upcoming clinical trials. Undoubtedly, the field
of RNA therapeutics is currently undergoing a major
expansion, and the potential for using RNA drugs for
personalized medicine and immunotherapy as well as to
address genetic, infectious, and chronic diseases will en-
sure the continued development of RNA therapeutics
for years to come.
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